Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
A strong upward trajectory in earnings before interest, tax, depreciation and amortization (EBITDA) is evident over the six-year period from 2016 to 2021. While growth remained relatively flat between 2016 and 2017, a significant acceleration occurred starting in 2018, culminating in a peak value of 4,984 million US dollars by September 30, 2021.
- EBITDA Growth Patterns
- EBITDA increased from 2,576 million US dollars in 2016 to 4,984 million US dollars in 2021, representing a substantial overall expansion of operating cash flow potential. A notable surge occurred between 2017 and 2018, where the value rose from 2,585 million to 3,857 million US dollars. Despite a moderate contraction in 2020 to 3,667 million US dollars, a strong recovery followed in 2021, marking the highest EBITDA level in the analyzed period.
- Operational Efficiency and Non-Cash Charges
- The variance between EBITDA and Earnings before interest and tax (EBIT) suggests a significant increase in depreciation and amortization expenses over time. Between 2016 and 2017, the difference was approximately 1.1 billion US dollars; however, by 2021, this gap widened to approximately 2.27 billion US dollars. This trend indicates a heavier asset base or significant capital investments during the latter half of the period.
- Net Income Divergence
- A decoupling is observed between EBITDA and Net Income, particularly in 2018. While EBITDA climbed to 3,857 million US dollars in 2018, Net Income dropped sharply to 311 million US dollars. This disparity suggests that while core operational profitability improved, the bottom line was heavily impacted by non-operating expenses, interest, taxes, or one-time non-cash charges during that fiscal year.
- Profitability Stability
- The stability of EBITDA compared to Net Income indicates that the core business operations remained more resilient than the final net earnings. The recovery in 2021 shows synchronized growth across all metrics, with EBITDA, EBIT, and Net Income all reaching their respective period highs, suggesting a period of high operational efficiency and favorable financial conditions.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Enterprise Value to EBITDA Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 89,222) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 4,984) |
| Valuation Ratio | |
| EV/EBITDA | 17.90 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| Abbott Laboratories | 15.60 |
| Elevance Health Inc. | 8.99 |
| Intuitive Surgical Inc. | 36.09 |
| Medtronic PLC | 14.56 |
| UnitedHealth Group Inc. | 18.28 |
| EV/EBITDA, Sector | |
| Health Care Equipment & Services | 15.96 |
| EV/EBITDA, Industry | |
| Health Care | 22.15 |
Based on: 10-K (reporting date: 2021-09-30).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Enterprise value (EV)1 | 84,640) | 80,969) | 89,200) | 85,173) | 55,792) | 45,755) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 4,984) | 3,667) | 4,068) | 3,857) | 2,585) | 2,576) | |
| Valuation Ratio | |||||||
| EV/EBITDA3 | 16.98 | 22.08 | 21.93 | 22.08 | 21.58 | 17.76 | |
| Benchmarks | |||||||
| EV/EBITDA, Competitors4 | |||||||
| Abbott Laboratories | 17.42 | — | — | — | — | — | |
| Elevance Health Inc. | 10.05 | — | — | — | — | — | |
| Intuitive Surgical Inc. | 44.10 | — | — | — | — | — | |
| Medtronic PLC | 24.41 | — | — | — | — | — | |
| UnitedHealth Group Inc. | 17.39 | — | — | — | — | — | |
| EV/EBITDA, Sector | |||||||
| Health Care Equipment & Services | 18.05 | — | — | — | — | — | |
| EV/EBITDA, Industry | |||||||
| Health Care | 14.33 | — | — | — | — | — | |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
3 2021 Calculation
EV/EBITDA = EV ÷ EBITDA
= 84,640 ÷ 4,984 = 16.98
4 Click competitor name to see calculations.
Analysis of the financial metrics from 2016 to 2021 reveals a period of valuation expansion followed by a sharp correction in the EV/EBITDA multiple, driven by diverging growth rates between enterprise value and operating performance.
- Enterprise Value (EV) Evolution
- Enterprise value exhibited a strong upward trajectory from September 30, 2016, to September 30, 2019, increasing from 45,755 million to a peak of 89,200 million. A subsequent decline was noted in 2020 to 80,969 million, followed by a modest recovery to 84,640 million by the end of the 2021 period.
- EBITDA Performance
- Earnings before interest, tax, depreciation, and amortization showed minimal growth between 2016 and 2017, but experienced a significant surge in 2018, rising to 3,857 million. After a temporary decline to 3,667 million in 2020, EBITDA reached its highest level in the observed period in 2021, totaling 4,984 million.
- EV/EBITDA Ratio Dynamics
- The valuation multiple underwent a distinct expansion phase between 2016 and 2018, rising from 17.76 to 22.08. This elevated valuation remained stable through 2020, fluctuating minimally around the 22.00 mark. A sharp contraction is observed in 2021, with the ratio dropping to 16.98, the lowest point in the six-year sequence. This compression was primarily the result of substantial EBITDA growth outpacing the growth in enterprise value during that fiscal year.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?